Theravance Biopharma
TBPH
116 hedge funds and large institutions have $655M invested in Theravance Biopharma in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 28 reducing their positions, and 23 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 28
46% more capital invested
Capital invested by funds: $449M → $655M (+$206M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
2.03% less ownership
Funds ownership: 82.56% → 80.53% (-2%)
3% less funds holding
Funds holding: 119 → 116 (-3)
76% less call options, than puts
Call options by funds: $978K | Put options by funds: $4.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$22.7M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$15M |
| 3 |
Morgan Stanley
New York
|
+$8.28M |
| 4 |
NM
Newtyn Management
New York
|
+$7.86M |
| 5 |
D.E. Shaw & Co
New York
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.4M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$17.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$12.2M |
| 4 |
Millennium Management
New York
|
-$8.04M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
-$5.5M |
TBPH Hedge Fund Activity: Q4 2021 in Review
116 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2021, worth a combined $655M — up 46% from $449M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TBPH and 21 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 50 added.
The largest buyer was Weiss Asset Management, opening a new position worth an estimated $22.7M. The largest seller was Point72 Asset Management, cutting an estimated $28.4M.
- 116 institutional investors held Theravance Biopharma (TBPH) as of Q4 2021, down from 119 in Q3 2021.
- Funds reported $655M of Theravance Biopharma stock for Q4 2021, up 46% quarter-over-quarter.
- 21 funds opened new Theravance Biopharma positions in Q4 2021 and 23 closed out, a net change of -2 holders.
- The largest Theravance Biopharma buyer in Q4 2021 was Weiss Asset Management, an estimated $22.7M added.
- The largest Theravance Biopharma seller in Q4 2021 was Point72 Asset Management, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2021.